Antitumor activity of metabolites of 1-hexylcarbamoyl-5-fluorouracil and related compounds against L1210 leukemia in vivo and L5178Y lymphoma cells in vitro.
Antitumor activity of metabolites of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and related compounds was examined in vivo and in vitro. Carboxypentyl and carboxypropyl carbamoyl derivatives of 5-fluorouracil (FU) were moderately active against L1210 by oral administration but less active by intraperitoneal administration. However, 5-hydroxy- and 5-oxo-hexylcarbamoyl derivatives of FU were markedly or moderately active against the leukemia by both oral and intraperitoneal administrations. Therapeutic ratios for the metabolites were less than that for HCFU by both oral and intraperitoneal administrations. Metabolites of HCFU had growth inhibitory activity against L5178Y in vitro similar to alkylcarbamoyl derivatives of FU. Activity of metabolites was lower than that of FU and higher than that of HCFU in vitro. It means that HCFU is converted into FU through active intermediate metabolites in vivo.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000494:pharmacology; D007939:Leukemia L1210 / Q000188:drug therapy; D007940:Leukemia L5178 / Q000188:drug therapy; D008297:Male; D051379:Mice
D000970:Antineoplastic Agents; C017367:carmofur; D005472:Fluorouracil